Novartis Pharmaceuticals
East Hanover, New Jersey, 07936, United States
NCT Number: NCT00353912
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
East Hanover, New Jersey, 07936, United States
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Novartis
Industry
A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01206062
Brain Diseases, Cardiovascular Diseases
Winston-Salem, North Carolina, United States
View Trial DetailsNCT02694432
Cardiovascular Diseases, Heart Murmurs
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT03360669
Cardiovascular Diseases, Heart Murmurs
Montreal, Quebec, Canada
View Trial DetailsNCT00387517
Cardiovascular Diseases, Heart Murmurs
East Hanover, New Jersey, United States
View Trial Details